{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=23",
    "query": {
      "intervention": "Part 3",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 4019,
    "total_pages": 402,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T17:05:35.307Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05356377",
      "title": "Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Phenylketonurias"
      ],
      "interventions": [
        {
          "name": "Pegvaliase-Pqpz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 6,
      "start_date": "2022-05-25",
      "completion_date": "2025-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-29",
      "last_synced_at": "2026-11-11T17:05:35.307Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Columbia, Missouri",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05356377"
    },
    {
      "nct_id": "NCT06970301",
      "title": "A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Study Participants"
      ],
      "interventions": [
        {
          "name": "glovadalen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2025-04-28",
      "completion_date": "2026-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-11-11T17:05:35.307Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06970301"
    },
    {
      "nct_id": "NCT06318975",
      "title": "Text-Based Messaging Strategies for Preventing Subsequent Problematic Alcohol Use",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Drinking",
        "Binge Drinking",
        "Text Messaging"
      ],
      "interventions": [
        {
          "name": "Brief Alcohol Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Automated and Targeted Text Messages",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7000,
      "start_date": "2023-12-01",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-11-11T17:05:35.307Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06318975"
    },
    {
      "nct_id": "NCT07903675",
      "title": "Effectiveness of the Autism Pupil Screen (APS) Detect Pupillometer for Identifying Autism Spectrum Disorder (ASD) in Routine Healthcare",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Autism Pupil Screen (APS) Detect PLR Assessment #1",
          "type": "DEVICE"
        },
        {
          "name": "Modified Checklist for Autism in Toddlers, Revised with Follow-up (M-CHAT/R-F)",
          "type": "OTHER"
        },
        {
          "name": "Social Responsiveness Scale, Second Edition (SRS-2)",
          "type": "OTHER"
        },
        {
          "name": "Autism Diagnostic Observation Schedule, Second Edition (ADOS-2)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Mullen Scales of Early Learning (MSEL)",
          "type": "OTHER"
        },
        {
          "name": "Adaptive Behavior Assessment System, Third Edition (ABAS-3)",
          "type": "OTHER"
        },
        {
          "name": "Autism Pupil Screen (APS) Detect PLR Assessment #2",
          "type": "DEVICE"
        },
        {
          "name": "Autism Pupil Screen (APS) Detect Assessment #3",
          "type": "DEVICE"
        },
        {
          "name": "Well-child check",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER",
        "DIAGNOSTIC_TEST",
        "PROCEDURE"
      ],
      "sponsor": "Schweitzer Engineering Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "24 Months",
        "maximum_age": "60 Months",
        "sex": "ALL",
        "summary": "24 Months to 60 Months"
      },
      "enrollment_count": 330,
      "start_date": "2026-10-23",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-11T17:05:35.307Z",
      "location_count": 4,
      "location_summary": "Lewiston, Idaho • Moscow, Idaho • Pullman, Washington",
      "locations": [
        {
          "city": "Lewiston",
          "state": "Idaho"
        },
        {
          "city": "Moscow",
          "state": "Idaho"
        },
        {
          "city": "Pullman",
          "state": "Washington"
        },
        {
          "city": "Pullman",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07903675"
    },
    {
      "nct_id": "NCT01844557",
      "title": "Testing Accountability in Patient Adherence",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head And Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Swallowing Exercises",
          "type": "OTHER"
        },
        {
          "name": "Symptom Inventory",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2013-05",
      "completion_date": "2021-12",
      "has_results": false,
      "last_update_posted_date": "2019-09-11",
      "last_synced_at": "2026-11-11T17:05:35.307Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844557"
    },
    {
      "nct_id": "NCT07058077",
      "title": "A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Heterozygous Familial Hypercholesterolemia (HeFH)"
      ],
      "interventions": [
        {
          "name": "Enlicitide Decanoate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 153,
      "start_date": "2025-08-21",
      "completion_date": "2037-01-23",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-11T17:05:35.307Z",
      "location_count": 8,
      "location_summary": "Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 5 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07058077"
    },
    {
      "nct_id": "NCT04990739",
      "title": "Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "MTB-9655",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MetaboMed Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-06-30",
      "completion_date": "2024-01-31",
      "has_results": false,
      "last_update_posted_date": "2021-12-17",
      "last_synced_at": "2026-11-11T17:05:35.307Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04990739"
    },
    {
      "nct_id": "NCT03894046",
      "title": "Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acinetobacter Baumannii-calcoaceticus Complex",
        "Hospital-acquired Bacterial Pneumonia",
        "Ventilator-associated Bacterial Pneumonia",
        "Bacteremia",
        "Colistin Resistant ABC"
      ],
      "interventions": [
        {
          "name": "Sulbactam",
          "type": "DRUG"
        },
        {
          "name": "Durlobactam",
          "type": "DRUG"
        },
        {
          "name": "Colistin",
          "type": "DRUG"
        },
        {
          "name": "Imipenem/Cilastatin 500 mg/500 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Entasis Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2019-09-05",
      "completion_date": "2021-07-26",
      "has_results": true,
      "last_update_posted_date": "2023-02-01",
      "last_synced_at": "2026-11-11T17:05:35.307Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03894046"
    },
    {
      "nct_id": "NCT00876941",
      "title": "Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Drug Usage",
        "Drug Abuse",
        "Drug Dependence"
      ],
      "interventions": [
        {
          "name": "Standard Brief Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Enhanced Brief Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control: Information and Feedback",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 589,
      "start_date": "2009-04",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2014-10-02",
      "last_synced_at": "2026-11-11T17:05:35.307Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00876941"
    },
    {
      "nct_id": "NCT06188741",
      "title": "Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis 1",
        "Plexiform Neurofibroma"
      ],
      "interventions": [
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "1 Year to 8 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-08-27",
      "completion_date": "2032-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-11-11T17:05:35.307Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06188741"
    }
  ]
}